8th Mayo Clinic Symposium on Tumor Microenvironment and Cancer Therapeutics:
Role of precision medicine and targeted therapy in clinical practice

December 7-9, 2018
Sawgrass Marriott Golf Resort and Spa
Ponte Vedra Beach, Florida

Director: Debabrata Mukhopadhyay, Ph.D.
Co-Directors: Asher Chanan-Khan, M.D.
              Leslie Cooper, M.D.

Planning Committee
Alfredo Quiñones-Hinojosa, M.D.
Panagiotis Anastasiadis, Ph.D.
Keith Knutson, Ph.D.
Daniel Billadeau, Ph.D.
Asher Chanan-Khan, M.D.
Leslie Cooper, M.D
Robert Diasio, M.D.
Debabrata Mukhopadhyay, Ph.D.
Steven Rosenfeld, M.D., Ph.D.
Tushar Patel, M.B., Ch.B.
Vijay Shah, M.D.
Robert Smallridge, M.D.
Priyabrata Mukherjee, Ph.D.,
Bengt Fadeel, M.D., Ph.D.

© Mayo Foundation for Medical Education and Research
**Table of Contents**

- Program Schedule ........................................................................................................ 1
- Course Description and Objectives.............................................................................. 8
- Continuing Education Credit ....................................................................................... 9
- Faculty ........................................................................................................................ 11
- Faculty Disclosure ..................................................................................................... 13
- Educational Grants ..................................................................................................... 15
- Lectures ...................................................................................................................... 17
- Abstracts .................................................................................................................... 56
Friday, December 7, 2018

7:00 a.m. Continental Breakfast and Registration

8:00 a.m. **Section I: Welcome and Introduction**  
*Asher Chanan-Khan, M.D., Mayo Clinic Jacksonville*

8:10 a.m. Pre-Plenary Assessment Utilizing Audience Response  
*Dev Mukhopadhyay, Ph.D., Mayo Clinic Jacksonville*

8:20 a.m. **Joseph Austin McCartney and Ruth McCartney Hauck Named Visiting Professorship Lecture**  
*Chair: Robert C. Smallridge, M.D, Deputy Director, Mayo Clinic Cancer Center.*

8:30 a.m. *Lesson learned from anti-PD-1/PD-L1 Cancer immunotherapy*  
*Lieping Chen M.D., Ph.D., Yale University*

8:55 a.m. Discussion

9:00 a.m. **Section II: Vascular biology and cell signaling**  
*Chair: Gopal Kundu, National Center for Cell Science, Pune, India*

9:10 a.m. *Control of vascular permeability via beta1-integrin*  
*Pipsa Saharinen, Ph.D., Wihuri Research Institute and Biomedicum, Helsinki*

9:30 a.m. Discussion

9:35 a.m. *Angiopoietin/Tie signaling: Still an attractive therapeutic target?*  
*Hellmut Augustin, Ph.D., German Cancer Research Center, Heidelberg*

9:55 a.m. Discussion

10:00 a.m. *Short Talk (From Abstract)*  
*Aneel Paulus, M.D., Mayo Clinic Jacksonville*

10:10 a.m. Discussion

10:15 a.m. Coffee Break

10:35 a.m. **Section III: Microenvironment and diseases**  
*Chair: Resham Bhattacharya, Ph.D., University of Oklahoma*

10:45 a.m. *The role of endothelial cilia in brain vascular patterning in vertebrates.*  
*Ramani Ramchandran, Ph.D., Medical College of Wisconsin*

11:05 a.m. Discussion
11:10 a.m. Circulating exosomes: A novel mechanism for the ischemic heart to recruit bone marrow cells
Gangjian Qin, MD, The University of Alabama at Birmingham
11:30 a.m. Discussion

11:35 a.m. Angiopellosis: a "group ticket" for cancer metastasis?
Ke Cheng, Ph.D. North Carolina State University
11:55 a.m. Discussion

12:00 p.m. Time-course of metabolic and soft tissue changes in pre-diagnostic pancreatic cancer
Suresh Chari M.D. Mayo Clinic Rochester
12:20 p.m. Discussion

12:25 p.m. Lunch

1:20 p.m. Section IV: Molecular basis of vascular diseases
Chair: Ying Wang, M.D., Ph.D., Mayo Clinic Jacksonville

1:30 p.m. Homeostasis of endothelial cell junctions in glioblastoma
Arie Horowitz, Sc.D., Thomas Jefferson University
1:50 p.m. Discussion

1:55 p.m. Blood-brain barrier and tumor-immune interfaces
Calvin Kuo, M.D., Ph.D., Stanford University
2:15 p.m. Discussion

2:20 p.m. Liver Kinase B1 in Tumor Angiogenesis
Ming-Hui Zou, MD PhD, Georgia State University
2:40 p.m. Discussion

2:45 p.m. Evidence for biochemical barrier restoration: Topical solenopsin analogs improve inflammation and acanthosis in the KC-Tie2 mouse model of psoriasis
Jack Arbiser, M.D., Ph.D., Emory University School of Medicine
3:05 p.m. Discussion

3:10 p.m. Young Investigator Award (Short Talk): (From Abstract)
Ling Wang, M.D., Ph.D., Medical College of Wisconsin
3:20 p.m. Discussion

3:25 p.m. Coffee Break

3:50 p.m. Section V: Microenvironment and Cell Signaling
Chair: Derek Radisky, Ph.D., Mayo Clinic Jacksonville

4:00 p.m. Protein Kinase Ciota: Oncogene and Therapeutic target
Alan Fields, Ph.D., Mayo Clinic Jacksonville
4:20 p.m. Discussion

4:25 p.m. *Inflammatory Mediators: Potential therapeutic targets in Pancreatic Cancer*
*S. Perwez Hussain, Ph.D., National Cancer Institute, NIH*

4:45 p.m. Discussion

4:50 p.m. KLF4 Signaling in ADM and Angiogenesis in Pancreatic Cancer
*Keping Xie, M.D., Ph.D., MD, Arizona State University*

5:10 p.m. Discussion

5:15 p.m. *Targeting the fibrotic microenvironment of pancreatic cancer*
*Peter Storz, Ph.D., Mayo Clinic Jacksonville*

5:35 p.m. Discussion

5:40 p.m. **Section VI: Poster Sessions/Reception**

---

**Saturday, December 8, 2018**

7:00 a.m. Continental Breakfast and Registration

8:00 a.m. **Section VII: Tumor Microenvironment crosstalk and cancer stemness in GBM**
*Chair: Panagiotis Z. Anastasiadis, Ph.D., Mayo Clinic Jacksonville*

8:10 a.m. *The critical importance of the blood tumor barrier in glioma therapy*
*Jann Sarkaria, M.D., Mayo Clinic Rochester*

8:30 a.m. Discussion

8:35 a.m. *Reconstructing tumor vessels for cancer therapy*
*Gabriele Bergers, Ph.D., Leuven Center for Cancer Biology, Belgium*

8:55 a.m. Discussion

9:00 a.m. *Wnt/β-catenin signaling in epigenetic regulation of gliomagenesis*
*Suyun Huang, M.D. Ph.D., Virginia Commonwealth University*

9:20 a.m. Discussion

9:25 a.m. *Partners in Crime: Brain Tumor Stem Cells and the Micoenvironment*
*Jeremy Rich, M.D., University of California San Diego*

9:45 a.m. Discussion

9:50 a.m. *“Go and Grow” in Glioblastoma*
*Steven Rosenfeld, M.D., Ph.D. Mayo Clinic Jacksonville*

10:10 a.m. Discussion
10:15 a.m.  Coffee Break

10:40 a.m.  Section VIII:

Mayo Clinic–Karolinska Institutet Joint Workshop on Nanotechnology in Medicine

Supported by: The Swedish Foundation for International Corporation in Research and Higher Education (STINT) Grant
Conveners: Bengt Fadeel, M.D., Ph.D. (KI) and Dev Mukhopadhyay, Ph.D. (Mayo)

Chairs: Bengt Fadeel, M.D., Ph.D. and Priyabrata Mukherjee, Ph.D.

10:45 a.m.  Theranostic nanoparticles targeting both tumor and stromal cells for the treatment of drug resistant cancer
Lily Yang, M.D., Ph.D., Emory University
11:05 a.m.  Discussion

11:10 a.m.  Applications of Nanosensors to Understanding Biochemical Signaling Within the Human Body
Michael S. Strano, Ph.D., Massachusetts Institute of Technology
11:30 a.m.  Discussion

11:35 a.m.  Probing cellular processes using engineered nanoparticles.
Priyabrata Mukherjee, Ph.D., University of Oklahoma
11:55 p.m.  Discussion

12:00 p.m.  Lunch

1:00 p.m.  From Nanosafety to Nanomedicine: Focus on carbon-based nanomaterials for cancer treatment
Bengt Fadeel, M.D., Ph.D. Karolinska Institutet, Sweden
1:20 p.m.  Discussion

1:25 p.m.  HURying for cancer therapy
Rajagopal Ramesh, Ph.D. University of Oklahoma
1:45 p.m.  Discussion

1:50 p.m.  Ultrasmall particle therapies and modulation of the tumor microenvironment
Michelle Bradbury M.D., Ph.D., Memorial Sloan Kettering
2:10 p.m.  Discussion

2:15 p.m.  Nanoparticles in radiation oncology – the road traveled, the road ahead
Sunil Krishnan, M.D. Ph.D. MD Anderson Cancer Center, TX
2:35 p.m.  Discussion

2:40 p.m.  Biological nanoparticles as therapeutic agents
3:00 p.m. Discussion

3:05 p.m. Young Investigator Talk
Santanu Bhattacharya, Ph.D., Mayo Clinic Jacksonville

3:20 p.m. Young Investigator Talk
Georgios A. Sotiriou, Dr. Sc., Karolinska Institutet, Sweden

3:35 p.m. Coffee Break

4:00 p.m. Section IX: Microenvironment and disease progression
Chair: Nicole R. Murray, Ph.D. Mayo Clinic Jacksonville

4:10 p.m. Unexpected contribution of lymphatic vessels to promotion of distant metastatic tumor spread
Michael Detmar, M.D., Swiss Federal Institute of Technology

4:30 p.m. Discussion

4:35 p.m. Mechanisms of lymphangiogenesis and lymphatic valve formation.
Tsutomu Kume, Ph.D., Northwestern University

4:55 p.m. Discussion

5:00 p.m. Is WT1 gene a tumor suppressor or oncogene?
Zigang Dong, M.D., Ph.D., The Hormel Institute, University of Minnesota

5:20 p.m. Discussion

5:30 p.m. Section X: Poster Session and Reception

Supported by The Swedish Foundation for International Corporation in Research and Higher Education (STINT) Grant

6:30 p.m. Section XI: Travel Scholarships/Oral Presentations and Dinner

Supported by The Swedish Foundation for International Corporation in Research and Higher Education (STINT) Grant

Chairs: Tushar C. Patel, M.B., Ch.B, Mayo Clinic Jacksonville,
       Leslie Cooper M.D., Mayo Clinic Jacksonville

Travel Award Winners
Young Faculty Scholarship Winners
Sunday, December 9, 2018

7:00 a.m.  Continental Breakfast and Registration

8:00 a.m.  **Section XII: Precision therapy targeting microenvironment and Clinical Outcomes**
*Chair: John A. Copland, Ph.D. Mayo Clinic Jacksonville*

8:10 a.m.  *Disruption of the immunosuppressive microenvironment in Mantle cell lymphoma with Bromodomain inhibitors*
Eduardo Sotomayor M.D., George Washington Cancer Center

8:30 a.m.  Discussion

8:35 a.m.  *Precision therapy of angiocrine signaling: Epigenetic mechanisms regulate inflammatory chemokine expressions in alcoholic hepatitis*
Vijay Shah, M.D., Mayo Clinic Rochester

8:55 a.m.  Discussion

9:00 a.m.  *Antibody therapy in human myeloma: hints coming from basic science*
Fabio Malavasi, M.D., University of Torino Medical School, Italy

9:20 a.m.  Discussion

9:25 a.m.  *Complimentary targeting of the PTCL epigenome and immune micro environment*
Owen A. O'Connor, M.D. New York University Cancer Institute

9:45 a.m.  Discussion

9:50 a.m.  **Coffee Break**

10:15 a.m.  *Vaccines for the treatment and prevention of cancer*
Keith L. Knutson, Ph.D. Mayo Clinic Jacksonville

10:35 a.m.  Discussion

10:40 a.m.  *Notch responsive miR-322/503 cluster regulates neovascularization through HIF-1 alpha signal*
Yao Liang Tang, MD, PhD, Augusta University

11:00 a.m.  Discussion

11:05 a.m.  **Section XIII: Folkman Lectureship Forum**
*New Horizon of Cancer Research: from Biomarker Discovery to Therapy*

Moderators:  Jack Arbiser, M.D., Ph.D., Emory University School of Medicine
Asher Chanan-Khan, M.D., Mayo Clinic Jacksonville
Panel members:

Kenichi Takeshita, M.D. Sorrento Therapeutics, Inc.
Lieping Chen M.D., Ph.D., Yale University
Stephen J. Noga M.D., Ph.D. Takeda, Pharmaceuticals
Suresh Chari M.D. Mayo Clinic Rochester

Section XIV:

11:45 p.m.  Post-Plenary Assessment Utilizing Audience Response
Dev Mukhopadhyay, Ph.D., Mayo Clinic Jacksonville

11:55 p.m.  Vote of Thanks
Leslie Cooper M.D., Mayo Clinic Jacksonville

12:00 p.m.  Adjourn.

Thank you for attendance!
Course Description
This symposium brings together basic scientists, clinical experts and industry partners in the field of tumor microenvironment, immune therapy, anti-angiogenesis and targeted therapy. Hence, this symposium will facilitate the exchange of ideas and new scientific direction involving basic biology and pathways that eventually lead to new individualize therapy for patients. Clinician scientists will present the results of ongoing clinical trials on targeted therapy including immune therapy, anti-angiogenic therapy and others. Novel genetic and imaging methods to assess alteration of tumor microenvironment for monitoring the effectiveness of therapeutic responses in the both pre-clinical and clinical trials will be discussed. Different clinical challenges and benefits of new therapeutic avenues including cardio-oncology will be presented. Overall, it is hoped that this symposium will assist in establishing strong collaborations among leading national, international, and Mayo Clinic experts in the field.

Course Learning Objectives
Upon conclusion of this program, participants should be able to:

- Critically assess the role of tumor microenvironment and angiogenesis in different pathological situations.
- Analyze the molecular pathways in tumor stroma formation and immune-angiogenesis crosstalk.
- Identify the importance of tumor stroma formation in cancer progression and metastasis and based on that developing targeted therapy.
- Evaluate precision therapy based on genetic knowledge as a potential target for future cancer therapy.
- Application of nanomedicine for targeted drug delivery.
- Onco-cardiology
- Cardiovascular remodeling and role of immune cells in cardiac diseases.
- Building a collaborative platform where basic scientists and clinicians can interface.

Intended Audience
- Clinicians involved in cancer-related practice or research
- Laboratory scientists
- Translational researchers
- Industry partners
- Graduate or medical students
- Postdoctoral fellows or residents
- Others with an interest or with backgrounds in Oncology, Cell biology, immunology and cancer immune therapy, cardiovascular biology and developmental biology, myeloma, cancer, angiogenesis and related clinical trials, lymph angiogenesis, extracellular matrix, and anti-angiogenic therapy in differential tumors.
Continuing Education Credit

Accreditation Statement:
In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

College of Medicine, Mayo Clinic, designates this live activity for a maximum of 17.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Other health care professionals will be provided a certificate of attendance for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

CME Record of Attendance

MCSCPD will provide electronic Record of Attendance Certificates through the website and registration system. Paper certificates will no longer be provided.

Upon conclusion of the CME activity, and completion of any required course materials, you will be able to claim credits commensurate with your participation at the CME activity.

Directions will be provided on how to claim your credit and print a certificate. A copy of the record of attendance will remain available in your personal account and can be printed at any time.

The Record of Attendance can be used for requesting credits in accordance with state licensing boards, specialty societies, or other professional associations.

CME Activity Evaluation

The faculty and overall course CME evaluations will be provided electronically through the website and registration system.

All attendees are invited to complete a Faculty Evaluation and an overall course CME activity evaluation. Course Directors use this feedback to maintain and improve the caliber of presentations in future courses. Your input is greatly appreciated. Thank you in advance for completing the evaluations.

Directions will be provided on where to complete these evaluations.

Taping of Sessions

Audio or visual taping by participants is not permitted.
**Smoking Policy**

In keeping with Mayo Clinic policy, smoking is not permitted in any of the meeting rooms or course facilities during Mayo-sponsored activities.

**Electronic Devices**

As a courtesy to other attendees, please turn off or place in silent mode all cell phones, pagers, PDA’s, laptop computers, etc.

**Disclaimer**

The material presented in this continuing medical education program is made available by the Mayo Clinic College of Medicine (MCCM) for educational purposes only. This material is not intended to represent the only, or necessarily the best, methods or procedures appropriate for the medical situation discussed, but rather is intended to present an approach, view, statement or opinion of the authors or presenters that may be helpful or of interest to other practitioners. As an attendee, you agree to participate in this medical education program sponsored by MCCM with full knowledge and awareness that you waive any claim you may have against MCCM or Mayo Clinic for reliance on any information presented in this educational program. The approval of the U.S. Food and Drug Administration is required for procedures and drugs that are considered experimental. Instrumentation systems discussed and/or demonstrated in or at this program may not yet have received FDA approval.

All of the proceedings of this program, including the presentation of scientific papers, are intended for limited publication only, and all property rights in the material presented, including common-law copyright, are expressly reserved by the speaker, MCCM or Mayo Clinic. No statement of presentation made is to be regarded as dedicated to the public domain. Any sound reproduction, transcript or other use of the material presented at this course without the permission of MCCM is prohibited to the full extent of common-law copyright in such material.

Attendance at this Mayo course does not indicate nor guarantee competence or proficiency in the performance of any procedures that may be discussed or taught in this course.
Faculty

Program Directors

Debabrata Mukhopadhyay, Ph.D.  Ascher Chanan-Khan, M.D.
Leslie Cooper, M.D.

Program Planning Committee

Alfredo Quiñones-Hinojosa, M.D.  Debabrata Mukhopadhyay, Ph.D.
Panagiotis Anastasiadis, Ph.D.  Steven Rosenfeld, M.D., Ph.D.
Keith Knutson, PhD.  Tushar Patel, M.B., Ch.B.
Daniel Billadeau, Ph.D.  Vijay Shah, M.D.
Ascher Chanan-Khan, M.D.  Robert Smallridge, M.D.
Leslie Cooper, M.D  Priyabrata Mukherjee, Ph.D.
Robert Diasio, M.D.  Bengt Fadeel, M.D., Ph.D.

Mayo Clinic Faculty

Asher Chanan-Khan, M.D.  Steven Rosenfeld, M.D., Ph.D.
Keith Knutson, PhD.  Tushar Patel, M.B., Ch.B.
Leslie Cooper, M.D  Vijay Shah, M.D.
Robert Smallridge, M.D.  Suresh Chari M.D.
John Copland, Ph.D.  Steven Rosenfeld, M.D., Ph.D.
Jann Sarkaria, M.D.  Panagiotis Anastasiadis, Ph.D.
Ying Wang, M.D., Ph.D.  Santanu Bhattacharya, Ph.D.
Peter Storz, Ph.D.  Alan Fields, Ph.D.,
Derek Radisky, Ph.D.  Evetter Radisky, Ph.D.

Guest Faculty

Jack Arbiser, M.D., Ph.D., Emory University, School of Medicine
Hellmut Augustin, Ph.D., German Cancer Research Center and Heidelberg University
Resham Bhattacharya, Ph.D., University of Oklahoma
Liping Chen M.D., Ph.D., Yale University
Pipsa Saharinen, Ph.D., Wihuri Research Institute and Biomedicum, Helsinki
Gangjian Qin, MD, The University of Alabama at Birmingham
Ke Cheng, Ph.D. North Carolina State University
Arie Horowitz, Sc.D., Thomas Jefferson University
Calvin Kuo, M.D., Ph.D., Stanford University
Ming-Hui Zou, MD PhD, Georgia State University
S. Perwez Hussain, Ph.D., National Cancer Institute, NIH
Keping Xie, M.D., Ph.D., MD, Arizona State University
Gabriele Bergers, Ph.D., Leuven Center for Cancer Biology, Belgium
Suyun Huang, M.D. Ph.D., Virginia Commonwealth University
Jeremy Rich, M.D., University of California San Diego
Lily Yang, M.D., Ph.D., Emory University
Michael S. Strano, Ph.D., Massachusetts Institute of Technology
Priyabrata Mukherjee, Ph.D., University of Oklahoma
Bengt Fadeel, M.D., Ph.D. Karolinska Institutet
Rajagopal Ramesh, Ph.D. University of Oklahoma
Michelle Bradbury M.D., Ph.D., Memorial Sloan Kettering
Sunil Krishnan, M.D. Ph.D. MD Anderson Cancer Center
Georgios A. Sotiriou, Dr. Sc., Karolinska Institutet
Michael Detmar, M.D., Swiss Federal Institute of Technology
Tsutomu Kume, Ph.D., Northwestern University
Zigang Dong, M.D., Ph.D., The Hormel Institute, University of Minnesota
Eduardo Sotomayor M.D., George Washington Cancer Center
Fabio Malavasi, M.D., University of Torino Medical School
Owen A. O'Connor, M.D. New York University Cancer Institute
Yao Liang Tang, MD, PhD, Augusta University
Kenichi Takeshita, M.D. Sorrento Therapeutics, Inc.
Stephen J. Noga M.D., Ph.D. Takeda, Pharmaceuticals
DISCLOSURE SUMMARY TO CME PARTICIPANTS

As a provider accredited by ACCME, College of Medicine, Mayo Clinic (Mayo School of CME) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program who have disclosed…

### Relevant financial relationship(s) with industry:

<table>
<thead>
<tr>
<th>Name</th>
<th>Relationship/Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calvin Kuo, M.D., Ph.D.</td>
<td>Consultant: Surrozen, Bio Techne</td>
</tr>
<tr>
<td></td>
<td>Stock Holder: Surrozen, Toma Biosciences</td>
</tr>
<tr>
<td>Eduardo Sotomayor M.D.</td>
<td>Consultant: Astra-Zeneca, Kite, Bayer,</td>
</tr>
<tr>
<td></td>
<td>Speaker’s Bureau: Pharmacyclics, Seattle Genetics and Janssen</td>
</tr>
<tr>
<td>Lieping Chen, M.D., Ph.D.</td>
<td>Consultant: NextCure, Vcanbio, GenomicCare, Pfizer, Tayu</td>
</tr>
<tr>
<td></td>
<td>Grant/Research support: NextCure</td>
</tr>
<tr>
<td>Michelle Bradbury M.D., Ph.D.</td>
<td>Consultant: Elucida Oncology</td>
</tr>
<tr>
<td>Kenichi Takeshita, M.D.</td>
<td>Employee: Sorrento Therapeutics, Inc.</td>
</tr>
<tr>
<td>Fabio Malavasi, M.D.</td>
<td>Speaker’s Bureau: Sanofi, Tusk Immunotherapeutics and Janssen</td>
</tr>
<tr>
<td></td>
<td>Grant/Research support: Janssen</td>
</tr>
<tr>
<td>Stephen J. Noga M.D., Ph.D.</td>
<td>Employee: Takeda, Pharmaceuticals</td>
</tr>
<tr>
<td>Ke Chang, Ph.D</td>
<td>Consultant: BreStem Therapeutics Inc and Xollent Biotech Inc.</td>
</tr>
<tr>
<td></td>
<td>Stock Shareholders: BreStem Therapeutics Inc and Xollent Biotech</td>
</tr>
</tbody>
</table>

### No relevant financial relationship(s) with industry:

<table>
<thead>
<tr>
<th>Name</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Jack Arbiser, M.D., Ph.D.,</td>
<td></td>
</tr>
<tr>
<td>Sanchari Bhattacharya</td>
<td></td>
</tr>
<tr>
<td>Hellmut Augustin, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Resham Bhattacharya, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Michael Detmar, M.D.</td>
<td></td>
</tr>
<tr>
<td>Suyun Huang, M.D.</td>
<td></td>
</tr>
<tr>
<td>Tsutomu Kume, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Gopal Kundu, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Priyabrata Mukherjee, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Debabrata Mukhopadhyay, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Janusz Rak, M.D., Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Ramani Ramchandran, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Jeremy Rich, M.D., Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Vijay Shah, M.D.</td>
<td></td>
</tr>
<tr>
<td>Michael Strano, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Keping Xie, M.D. Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Pipsa Saharinen, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Arie Horowitz, Sc.D.</td>
<td></td>
</tr>
<tr>
<td>S. Perwez Hussain, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Lily Yang, M.D., Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Bengt Fadeel, M.D., Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Rajagopal Ramesh, Ph.D.</td>
<td></td>
</tr>
</tbody>
</table>
Owen A. O'Connor, M.D.  
Gangjian Qin, M.D.  
Gabriele Bergers, Ph.D.  
Georgios A. Sotiriou, Dr. Sc.  
Yao Liang Tang, MD, PhD  
Zigang Dong, M.D., Ph.D.  
Sunil Krishnan, M.D. Ph.D.

References to off-label usage(s) of pharmaceuticals or instruments in their presentation:

Calvin Kuo, M.D., Ph.D.  
Eduardo Sotomayor M.D.  
Lieping Chen, M.D., Ph.D.  
Michelle Bradbury M.D., Ph.D.  
Fabio Malavasi, M.D.  
Kenichi Takeshita, M.D.  
Stephen J. Noga M.D., Ph.D.  
Ke Cheng, Ph.D.

NATIONAL PHYSICIAN PAYMENT TRANSPARENCY PROGRAM

Mayo Clinic College of Medicine complies with the requirements of the National Physician Payment Transparency Program OPEN PAYMENTS (Physician Payments Sunshine Act).
This course is supported in part by unrestricted educational grants from the following organization and companies in accordance with ACCME standards:

The Swedish Foundation for International Corporation in Research and Higher Education (STINT) Grant

Joseph Austin McCartney and Ruth McCartney Hauck Visiting Professorship

Millennium Pharmaceuticals Inc.

Pharmacyclics LLC
An Abbvie Company and Janssen Biotech, Inc.

Thanks To The Exhibitors For Their Support

Bristol-Myers Squibb Company

NanoString Technologies

Amgen Inc.

BTG Pharmaceuticals

Merck

Abbvie Company

Takeda
Support provided by the following Mayo Clinic departments:

Mayo Clinic Cancer Center

Cancer Biology Department

Cancer Discovery, Mayo Clinic Florida

Florida Department of Health Cancer Research Chair Fund